CHA₂DS₂‑VASc and CHA₂DS₂‑VA Scoring with Anticoagulation Guidance (2024 ESC)

Score Components and Calculation

• The CHA₂DS₂‑VASc score assigns 1 point each for congestive heart failure/LV dysfunction, hypertension, diabetes mellitus, vascular disease (prior MI, PAD, aortic plaque), age 65‑74 years, and female sex; 2 points each for age ≥ 75 years and prior stroke/TIA/thromboembolism. The maximum possible score is 9 points. 1

Updated Scoring System (CHA₂DS₂‑VA)

• The 2024 European Society of Cardiology (ESC) guidelines replace CHA₂DS₂‑VASc with CHA₂DS₂‑VA, removing the female‑sex point; the revised scale ranges from 0 to 8 points. 2

Anticoagulation Recommendations by CHA₂DS₂‑VA Score

• Score 0: No oral anticoagulation is recommended (Class III). 2
• Score 1: Oral anticoagulation should be considered (Class IIa). 2
• Score ≥ 2: Oral anticoagulation is recommended (Class I). 2

Stroke Risk by CHA₂DS₂‑VASc Score (Annual Rates)

Stroke rates increase progressively with higher CHA₂DS₂‑VASc scores, supporting risk‑adjusted anticoagulation decisions. 3

Choice of Anticoagulant

• Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation (Class I, strong evidence). 2
• Preferred DOAC agents: apixaban, dabigatran, edoxaban, rivaroxaban. [2][1]
• Warfarin remains the agent of choice for patients with mechanical heart valves or moderate‑to‑severe mitral stenosis. 2

DOAC Dosing (Standard Regimens)

• Apixaban: 5 mg twice daily; reduce to 2.5 mg twice daily if ≥ 2 of the following: age ≥ 80 years, weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL. 1
• Rivaroxaban: 20 mg once daily with the largest meal; reduce to 15 mg once daily if creatinine clearance (CrCl) 15–50 mL/min. 1
• Edoxaban: 60 mg once daily; reduce to 30 mg once daily if CrCl 15–50 mL/min. 1
• Dabigatran: 150 mg twice daily; reduce to 75 mg twice daily if CrCl 15–30 mL/min. 1

Clinical Recommendations

Antiplatelet Therapy

• Antiplatelet agents are not recommended as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation (Class III, strong evidence). 2

Periodic Risk Reassessment

• Ongoing reassessment of thromboembolic risk is mandatory because risk factors may evolve, potentially shifting patients from low‑ to high‑risk categories that warrant anticoagulation. (Class I, strong evidence). 2

Special Populations Requiring Anticoagulation Regardless of CHA₂DS₂‑VA Score

• All patients with atrial fibrillation and hypertrophic cardiomyopathy should receive oral anticoagulation irrespective of their CHA₂DS₂‑VA score. 2
• All patients with atrial fibrillation and cardiac amyloidosis should receive oral anticoagulation irrespective of their CHA₂DS₂‑VA score. 2

Anticoagulation Recommendations Based on the CHA₂DS₂‑VA Score (ESC 2024)

Updated Scoring System

• The European Society of Cardiology (ESC) 2024 guidelines replace the CHA₂DS₂‑VASc score with the simplified CHA₂DS₂‑VA score, removing the female‑sex point and creating a 0–8 point scale. Class I recommendation. 4

Stroke‑Risk Stratification and Anticoagulation Indication

• Score 0: Patients have an annual stroke risk of ≈0.04 % and derive no net clinical benefit from oral anticoagulation; therefore, anticoagulation is not recommended (Class III).
• Score 1: Oral anticoagulation should be considered after shared decision‑making because the overall annual stroke rate is ≈0.55 %, but the true risk varies markedly by the specific risk factor (≈1.96 %/year for vascular disease, ≈3.50 %/year for age 65–74). Most patients exceed the 1 % threshold that justifies anticoagulation. Class IIa recommendation. [4] [5]
• Score ≥ 2: Oral anticoagulation is recommended (Class I). Annual stroke rates increase from ≈0.83 % (score 2) to ≈7.78 % (score 8), clearly surpassing the threshold for net clinical benefit. 4

Antiplatelet Therapy

• Aspirin alone or aspirin + clopidogrel should not be used as an alternative to oral anticoagulation for stroke prevention in atrial fibrillation because antiplatelet agents are ineffective for this purpose. Class III recommendation. 4

Special Populations Requiring Anticoagulation Regardless of CHA₂DS₂‑VA Score

• All patients with atrial fibrillation and hypertrophic cardiomyopathy should receive oral anticoagulation (Class I). 4
• All patients with atrial fibrillation and cardiac amyloidosis should receive oral anticoagulation (Class I). 4

Ongoing Management

• Reassessment of thromboembolic risk at every clinical encounter is mandatory because risk factors evolve over time; this periodic reassessment is a Class I recommendation. 4